EHF in Oncology (Eng)

EXTREMELY HIGH FREQUENCY (EHF) THERAPY IN ONCOLOGY

It is a technical translation from Russian into English
Russian original of the article was published in
[Millimeter Waves in Biology and Medicine. 2003, N 1 (29), p. 3-19]

Mikhail Teppone, Romen Avakyan,

 

1. Application of MM Electromagnetic Radiation in Experimental Oncology

Study of biological effects caused by the electromagnetic radiation (EMR) has shown that exposure of living organisms to centimeter-wavelength radiation, prior to lethal dose of ionizing radiation, reduced their mortality for several times [A.Presman, 1968; S.Michaelson, 1963]. Similar effects were observed when a low-intensity millimeter-wavelength radiation was initially applied. Biological effects of MM EMR depended on its frequency, applied power, and exposure time [L.Sevastjanova et al., 1966, 1985].

Further experimental and clinical investigations were carried out into the following directions: MM EMR effects on tumor growth, hemo-protective effect of MM EMR and combination of EHF-therapy and conventional method, applied in oncology (surgery, anti-tumor medicines and X-ray therapy):

1) MM EMR does not increase the tumor growth, it has an inhibiting effect on transplanted sarcoma growth and prolongs the life of tested animals. Effect of the greatest inhibition of the tumor growth (up to the 60 %) was obtained when MM EMR was applied before as well as after transplantation of sarcoma [L.Mkrtchian et al., 1989; L.Sevastjanova, 1979; N.Deviatkov et al., 1991; S.Sit'ko et al., 1991].

2) In combination with anti-tumor medicines (vincristine, cyclophosphane, methotrexate, etc.), or with X-ray therapy, the EHF-radiation has a selective effect on the blood-making system. The character of effect depends on the order of EHF-application. When used prior to the ionizing radiation or anti-tumor medicines, EHF has a hemo-protective effect and prolongs the life of the experimental animals. However, it adversely affects the hemogenic process in marrow when applied after the lethal dose of ionizing radiation or anti-tumor medicines [L.Sevastjanova et al., 1966; L.Sevastjanova, 1979].

3) On the model of hypo plastic marrow, the initial exposure to EHF has increased the proliferation of the donor marrow. Survival of animals who then received a lethal dose of ionizing radiation reached 95-98 %. A significant weakening of marrow syndrome was observed in clinical conditions [N.Deviatkov et al., 1987; E.Zubenkova, 1991].

4) Experiment which was carried out on the rats demonstrated multiplane effect of the low-intensity pulsed microwave radiation of nanosecond duration with high peak power. A “new” modality of EHF-radiation did not affect the experimental animals, activated resistance of anticancer system of the body, inhibited induced cancer growth, and suppressed the Worker's carcinoma cells in vitro [N.Deviatkov et al., 1991, 1997].

Thus, the MM EMR exposure does not intensify the tumor growth and in combination with chemical and X-ray therapy, provides a hemo-protective effect.


2. EHF — THERAPY IN CLINICAL ONCOLOGY

Clinical researches have shown that EHF therapy does not stimulate the growth of the main and metastatic tumor source [I.Fasahkov, 1985; S.Pletnev et al., 1985, 1991; S.Pletnev, 1991] and on the contrary, it may suppress the tumor process [S.Sit'ko et al., 1991].

As an independent treatment, the EHF therapy is used in oncology for treatment of non-malignant tumors or as a palliative therapy reducing the pain and intoxication syndromes. In all other cases, EHF therapy could be applied in combination with surgery or chemical and X-ray therapy.

The following nosologic forms when EHF-therapy was used are presently known: gastric polyps and myoma uteri; non-malignant skin and testicular tumors, local fibroadenomatosis and fibroadenoma of mamma gland, malignant skin melanoma, cancer of the stomach, mammary gland, ovarian cancer, uterine body and cervical carcinoma, cancer of esophagus, lung, bowel and other [А.Dolgushina, 1997; V.Zaporozhan et al., 1993, 1995, 1997; R.Kabisov, 1991, 1992; N.Lian et al., 1995; D.Myasoedov et al., 1989; S.Pletnev et al., 1991, 1995; M.Teppone, 1991; I.Soloviev et al., 1992].

2.1. In the pre-surgery period, the EHF therapy treats a number of accompanying pathological states, including erosive-ulcer affection of the stomach and duodenum mucous membrane, acute condition of chronic inflammatory diseases of respiratory and digestive tract, etc.), and thus reduces the risk of surgical intervention. 

Application of EHF-therapy in pre- and post surgery period reduced the likelihood of such post-surgery complication as suppurative septic condition, hemorrhagic and atonic syndromes, and intensified the healing process of postoperative wounds and post-excision defects.

The treatment successfully stops the pain syndrome, which makes possible to reduce the dose or abolish analgesics and narcotic drug. In a number of cases EHF therapy prevents the development of relapses and metastases [E.Binyashevskii et al., 1992; V.Zaporozhan et al., 1995; D.Myasoedov et al.,1989; R.Kabisov, 1992; N.Lian et al., 1995; S.Pletnev et al., 1991; I.Soloviev et al., 1992; S.Sit'ko et al., 1993].

2.2. It is particularly important to underscore the effect of EHF-radiation on course of wound process.
In alteration phase (pain, reddening, edema) the intensity of necrolysis and perifocal reactions is reduced, edema and hyperthermia are quickly removed, and no complications in form of protruding stitches is observed. Pain may be relieved after the very first exposure.

In regeneration phase, the granulation tissue never extends beyond the wound limits, epitelization begins earlier and uniformly from the wound bounder, the scar is never dense, which gives an excellent cosmetic effect. No keloid takes place. The wound is healed totally 5 to 6 days earlier than in usual course of the wound process [S.Pletnev, 1991].

In treatment of laser wounds the patients had no side reactions, pain and discomfort sense in the wound area were removed fast [S.Pletnev, 1991].


2.3. In the clinical oncology EHF-therapy is most widely applied as a hemo-stimulative and hemo-protective factor on a background of X-ray and chemical treatment. 

2.3.1. Exposure to EHF of patients having initially a low content of leukocytes in peripheral blood increased their level to a value making possible the chemical treatment [E.Binyashevskii et al., 1992; S.Pletnev, 1991; S.Sit'ko et al., 1993; V.Ivakin et al., 1997].

While preserving the anti-tumor effect of chemical medicines (5-fluoruracil, cyclophosphane, methotrexate), MM EMR reduces significantly their toxic effects (nausea, vomiting, diarrhea, weight loss, etc.) which allows a full-scale treatment, without changing the chemical therapy terms or rate. Leukocytes amount in peripheral blood stays in normal limits [R.Kabisov, 1992; S.Pletnev, 1991, 1995; S.Pletnev et al., 1985, 1987, 1991, 1992; V.Ivakin et al., 1997].

2.3.2. Prophylactic EHF-therapy in 60 % of cases prevented or weakened toxopathic symptoms usually caused while specific chemo-therapy by platidianum was applied [R.Kabisov, 1992].

2.3.3. Study of the functional activity of segmented neutrophiles by means of the spontaneous rosette test revealed decreasing rosette forming cells (before treatment — 3.42 + 0,21 %, after treatment — 2.06 + 0,26 %), what pointed on the high activity of these leukocytes and, probably, explained the mechanism of weakening the toxicity side effects observed during chemo-therapy [S.Pletnev et al., 1992].

2.3.4. Similar results were obtained when EHF was combined with X-ray therapy. Besides the hemo-protective effect, such manifestations of X-ray therapy as stomatitis, esophagitis, pulmonitis, cystitis, rectitis, etc. were less expressed, which made possible to conduct the full course of combined treatment, improve its results and cut the term from 18,0 + 4,0 to 6,5 + 1,5 days [R.Kabisov, 1992].


2.4. EHF-therapy of oncological patients may decrease or correct completely the main pathogenetic mechanisms of the neoplastic disease.

2.4.1. A pain syndrome was one of the most important and usual clinical sign of any tumor. The intensity of the pain may especially increase at the latest stages of disease. Most of patients (about 60 %) required special analgetic medicines including narcotic drugs.

After the treatment course of 10-20 sessions of EHF-therapy all the patients reduced the dose of remedies taken or grave up taking them at all. The anesthetic effect came immediately during the treatment seance and its duration was about 24 hours. The steady analgetic effect occurred after 2-3 seances of MRT [L.Mkrtchian et al., 1989; S.Pletnev et al., 1991, 1992; S.Sit'ko et al., 1993, etc.].

After Microwave resonance therapy 94 % of patients with oncopathology had anesthetic effect in varying degree. They recommended following Acupoints:

  • in cases of gynecology diseases — Du20, Sp6, Ren1, B30 and B27;
  • in cases of pulmonary diseases — Ren15, Ren22, B15, LI10 and Gb37;
  • in cases of urology diseases — Liv2, K12, H2, Sp6 and B25;
  • and in cases of gastrointestinal tract diseases — L7, Pc6, LI9, Ren8 and SJ5 [E.Binyashevskii et al., 1992; L.Mkrtchian et al., 1991].

2.4.2. In the cases of any neoplastic process including primary uterus cancer, patients had various kinds of T-cellular immune-deficient manifesting itself with the reduction of the lymphocytes quantity as well as reduction of the various subpopulation of the T-lymphocytes. After MRT the rise of T-cells was observed, especially by means of T-helpers and T-suppressors.

 

T- lymphocytes

T- “active” lymphocytes

T-helpers

T-suppressors

Before EHF-therapy (%):

40,0 + 3,1

23,0 + 2,1

27,2 + 1,8

13,1 + 1,1

After EHF-therapy (%):

47,2 + 3,4

28,5 + 1,8

31,0 + 3,6

16,0 + 2,0

Among healthy persons after EHF-exposure the quantity of the lymphocytes and monocytes had no significant changes. 

 

T- lymphocytes

T- “active” lymphocytes

T-helpers

T-suppressors

Before EHF-therapy (%):

58,0 + 3,6

28,5 + 2,2

37,5 + 2,9

19,5 + 1,3

After EHF-therapy (%):

58,5 + 3,9

29,5 + 2,3

38,5 + 3,4

20,0 + 1,7

2.4.3. The patients with cervical carcinoma had interferon status noticeably suppressed (in 25-40 % of cases), especially at II and III stages of the disease. After MRT/EHF-therapy the gamma-interferon synthesis increased from 20-40 unit/ml per titer to 95 unit/ml. In cases of the I stage of disease the gamma-interferon synthesis increased till the normal level - 120 unit/ml. Among the healthy persons the ability of mononuclears in peripheral blood to produce ྙ-interferon had not been changed by the MM EMR exposure [E.Binyashevskii et al., 1992; L.Kamalian et al., 1989; S.Sit'ko et al., 1991, 1993].

Thus EHF/MRT realized immunostimulating effect only in the case when the suppression of immune system took place and did not influence on normal immune status. 

2.4.4. Usual for oncological patients leukopenia is one of the counter-indication to begin both chemical and X-ray therapy.

Stimulation of leukopoiesis can be achieved by means of EHF-therapy with fixed frequencies (wavelengths: 5,6 and 7,1 mm) and EHF-therapy with individual therapeutic frequencies of MM EMR or MRT. Area of sternum, epigastrium, ethmoidal and occiput region were exposed by EHF in the first case, and the following acupoints were applied: K-7, L-10, SI-6, Ren-12, Ren-17, K-10, Gb-35 and Gb-39, in the second case.

In the both cases the leukocytes number in peripheral blood increased average from 2.5 thousand before treatment till 4.0-4.5 thousand after treatment. After leukopoiesis stimulation with MRT/EHF almost all patients could be treated by means of chemotherapy or X-ray [E.Binyashevskii et al., 1992; V.Ivakin et al. 1997; L.Kamalian et al., 1989; S.Pletnev et al., 1985, 1991; S.Sit'ko et al., 1993 etc.].

2.4.5. EHF-therapy normalized balance between peroxide oxidation of lipid (POL) and anti- oxidant system in the cancer patients' organism locally.

In the group of animals (rats) with induced cancer the increased level of malonic dialdehyde in the liver tissue was (518,0 + 15,7 nm/mg). After MRT it became less significantly (394,0 + 20,3 nm/mg), what correlated to positive effect of treatment.

Opposite dynamics of ascorbat-dependent POL in the tumor tissue was observed (after MRT - 261,2 + 10,8 nm/mg, in the control group — 178,9 + 9,6 nm/mg). Probably, increasing cell-toxic free radicals promotes destruction of the tumor cells [L.Mkrtchian et al., 1989; S.Sit'ko et al., 1991].

2.4.6. Besides, EHF-therapy resulted in stimulation of the non-specific adaptation capacity of the patients' body. The quantity of patients who had a “stress” reaction reduced from 12,0 to 3,7 %, while the patients whose “stress” response had transformed into “training” and “easy adaptation” (after L.Garkavi) responses increased in number [S.Pletnev et al., 1991; S.Pletnev, 1995].

Study of the stress and adaptogenic hormones before and after MRT have revealed normalization of increased level of ACTH, cortisone and adrenaline and decreased level of secretine (from 7,19 + 2,40 to 41,11 + 15,9 pg/ml) [S.Sit'ko et al., 1991].

2.5. Preventive EHF-therapy in oncology.
Study of the main mechanisms of tumor pathogenesis allows to apply EHF-therapy to decrease the risk of the cancer and prevent various neoplastic diseases uprising.

2.5.1. Tumor tissue secretes the substances increasing blood coagulation and lowering fibrinolytic ability. After MRT/EHF-therapy general coagulability potential of blood, including such factors as fibrinogen, fibrinogen B , prothrombine, clotting time and aggregability of thrombocytes decreased more than by 30 % [S.Sit'ko et al., 1993].

2.5.2. As it was mentioned above patients suffering from any neoplastic processes had humoral and cell immunodeficient. Application of MRT restored the ability of mononuclears in the peripheral blood to produce gamma-interferon and depressed the growth of experimental tumors. Probably, this fact may explain therapeutic activity of EHF-therapy while treatment of such neoplastic diseases as mammary gland or ovarian cancer, lymphoepithelioma, lymphogranulomatosis (Hodgkin's disease), etc.

During experiments with the white mouse it was demonstrated that preventive application of MRT on the acupoints St-36 and LI-4 decreased the growth of experimental tumors on the 40-60 %. In the clinical investigations they proved possibility to prevent transformation of the “pre-cancer” diseases into cancer [S.Sit'ko et al., 1993]. 

2.6. Application of EHF/MRT for incurable patients. 
While application of EHF/MRT for incurable patients the following problems are to be solved:
   1) improvement of the “health quality” due to the pain relief, narco-trancvillizing, detoxication, psychotherapeutic and other effects;
   2) life prolongation due to improvement of the specific (anti-cancer) and non-specific resistance of the patient's body: stimulation of the cells and humoral components of the immunity, treatment and prophylaxis of complications and accompanied diseases;
   3) improvement of the patient's condition to transfer him from the group of the “incurable” to the group where different methods of combined treatment could be applied, including radical surgery, chemo- or radio-therapy.

2.6.1. In spite of the lethal outcome and poor prognosis nevertheless one should analyze treatment results in cases of the advanced forms of cancer.

There were 39 patients suffering from oncological diseases of III-IV stages of various localization. Some of them have been undergone the palliative surgery, chemo- or radiotherapy. All patients were performed one or more courses of EHF-therapy with individual therapeutic frequencies or MRT.

Results of treatment were as following:

 

Patients who have already died

 

less than 1 month

1 - 6 months

7 - 12 months

Number of patient:

4

10

5

1) Patients died during the first month of treatment in the beginning of MRT had already grave condition and suffered from troublesome pain: obturated bowel tumor at the sygmoidostomy; mediastinal tumor with growing into trachea, bronchi, vessels and sternum; IV stage stomach carcinoma accompanied with cachexia and ascites; cancer of pancreas with growing into abdominal viscera and tissue and multiple metastases.

After MRT patients noticed improvement of the state of health, relief of pain syndrome, restoration of appetite and sleep.

2) The group of patients who died during 1-6 months of observation included following cancer localization: pancreas (4), liver, tongue, esophagus, lung, bowel and retroperitoneum.

As in the first group all patients noticed improvement of the state of health, restoration of appetite and sleep. Stable relief of pain allowed most of the patients to stop taking the analgesic medicines. There were no signs of cancer destruction. Besides, such symptoms as dyspnea, troublesome cough and hemoptysis (pulmonary cancer with obturation of the primary bronchus), choking and difficult swallowing (cancer of tongue and esophagus) and others were relieved or even stopped.

3) In the group of patients who lived from 6 months to 1 year: cancer of pancreas (2), papillosphyncter, lung and ovary results of treatment were the same as in the second group.

 

Patients which are under observation

 

1 - 4 months

5 -12 months

12-36 months

Number of patient:

6

5

6

4) The group of patients who are under treatment and observation yet includes the following cancer localization: mammary gland, pancreas, prostate, retroperitoneum, lung, sigmoid and other.

In this group pain syndrome relieved almost completely and there were no signs of the cancer progression.

2.6.2. Study presented above gave possibility to make following conclusions:

1) Positive clinical effect of treatment on symptomatic and syndrome level during MRT and nearest 1-3 weeks was obtained in 92 % of cases. Improvement of the “health quality” could be achieved in 82 % of patients;

2) EHF/MRT provides to stop the main clinical syndromes accompanied advanced cancer cases. Therapeutic efficacy of EHF/MRT was the same as in the cases of conventional medicines application;

3) Perhaps, during EHF/MRT the cancer loses such features of its “malignancy” as possibility to metastasize and grow through surrounding tissues and organs [B.Grubnik et al., 1997].


3. EHF-therapy of Non-Malignant Neoplasms

In cases of non-malignant neoplasms EHF-therapy was applied to treat the gastric polyps, myoma uteri and benign tumors from the ovaries. In these cases EHF-therapy used both as a mono-therapy and in combination with surgical treatment.

3.1. EHF-therapy of Gastric polyps.
3.1.1. Two treatment methods were used in mono-EHF-therapy.
   a) In the first case EHF-therapy with individual selection of exposure frequency (the so-called microwave resonance therapy - MRT) was applied. They exposed the acupoints with the lowest electrical resistance, including Ren-12, St-21, St-36, Sp-4, Ren-10, B-20, etc.). The exposure time was 20 minutes. The treatment course consisted of 8-12 sessions performed daily or every other day.
   b) In the second case EHF-puncture with individual selection of acupoints: St-36, Sp-3, Sp-4 and B-20 was applied. The fixed exposure frequency was equal to 53.53 GHz. Sessions were performed 1 or 2 times a week in process of 3 to 4 months. In the both cases the generator of MM EMR “G4-142” was used

After course of MRT, besides improvement of the stomach mucous membrane condition, the state of patients stabilized, i.e. polyps stopped growing, and no new polyps were formed in process of 2 years [E.Binyashevskii et al., 1992; I.Soloviev et al., 1992; S.Sit'ko et al., 1991];

By the end of EHF-puncture course the total disappearance of one or more polyps was observed in 36,4 % of cases, the size of polyps reduced 2 times and more — in 27,3 %, and 27,3 % of patients had 1/3 reduction of the polyps size [M.Teppone, 1991].

3.1.2. In those cases when endoscopic electric excision was used, the patients received MRT by a method described earlier. Pain syndrome was stopped in post-surgery period after the first session. Improved functional state of the stomach mucous membrane was observed, as well as restored motor activity of stomach which was usually weak. More than 90 % of patients had, after 2 weeks of treatment, a complete epitelization of post-excision defects [E.Binyashevskii et al., 1992; D.Myasoedov et al., 1989; I.Soloviev et al., 1992; S.Sit'ko et al., 1991].

Thus, the tests have shown that EHF-therapy is efficient not only in combined treatment, but also as a mono-therapy resulting in improved clinical and endoscopic characteristics.

3.2. EHF-therapy of Myoma Uteri.
They applied generators of MM EMR “Jav-I” (7.1 mm) or “Artsakh-02m”. The sternum of the area of the second rib level was exposed. Depending on the size of increased uterus, either conservative or surgical treatment was used. When the uterus size was less than after 10-weeks pregnancy, the EHF-therapy was used as a mono-therapy, or in combination with hormonal “norkolut” remedy. when the size exceeded the 10 weeks pregnancy, the EHF-therapy was used in a post-surgical period.

3.2.1. Conservative (non-surgical) treatment of myoma uteri.
45 minutes exposures were carried out daily, during 10 days since the 10th till 22nd days of the cycle.
The results of treatment were as follows. All patients felt and slept better after the first several sessions, and their psycho-emotional state had improved. After the treatment the pain syndrome was relieved, menstruation became less abundant and painful, while their length shortened in average for one day. Ultrasound testing has shown that in 50 % of cases the myomatoze nodes reduced in size by 4,88 + 1.54 mm, and in some cases even by 1.5 - 2.0 cm. Such parameters of the immune system as T-cells, predominantly helpers became normal.
In combination with hormonal “norkolut” remedy, the EHF-therapy allowed to twice cut the medicine dose and thus reduce its side effects. This has made possible the full-scale treatment [V.Zaporozhan et al., 1992, 1993, 1995].

The same results were obtained by another authors who applied EHF-therapy to treat myoma uteri. The complete disappearance of myomatoze nodules were observed in cases, when the size of uterus did not exceed 7-weeks pregnancy. If myoma sizes were more results were not so good [A.Arinushkina et al., 1997].

3.2.2. EHF-therapy after the myoma uteri surgery.
Sessions of treatment were applied 10 days after the surgery.
Most of patients had no post-surgical purulent septic complications. The immune system were either weakly depressed, or even normal.
In the both cases of myoma uteri treatment the stimulation of leukopoiesis and increase of segmental-nuclear leukocytes were observed. Besides, the hormonal level of the blood was normalized, mainly by means of progesterone level [V.Zaporozhan et al., 1991, 1993, 1995].

3.3. EHF-therapy of the patients with benign epithelial ovarian tumors.
The 45 minutes exposure of MM EMR (7,1 mm) were performed since the 8th day of the menstrual cycle, onto the sternum area in the site of the 2nd rib fixation. The first cycle consisting of 10 sessions was performed within 2 months after the operative removal of tumor, the second cycle — within 4 months. Examination of the patients' condition have been done 6 and 12 months after the surgery treatment.

The results of the treatment were as following: in cases of combined treatment (surgery and EHF) normalization of the prolactin, estrodiol, progesterone and follicle-stimulating hormones was obtained; the was no depression of the T- and B- components of immune system; activity of the proteolytic enzymes had tendency to normal level too; there was restoration of the balance between proteinase / inhibitors [V.Zaporozhan et al., 1997].

Thus, the hyperplastic processes in uterus may be efficiently treated by EHF-radiation used both as a mono- EHF- and in combination with hormonal or surgical treatment.


4. EHF-therapy of Malignant Neoplasm

In treatment of malignant neoplasm the EHF-therapy was used jointly with surgical, as well as chemical and ray therapy.

Generators of MM EMR “Jav-I” (5,6 and 7,1 mm), “Artsakh-02m” with noise-like or combined radiation and “Luch-EHF” (7,1 mm) were applied. Exact methods of treatment depended on the character of radical therapy.

4.1. Treatment of the Skin Melanoma.
EHF-therapy was used after the surgical (laser) removal of the primary tumor source. The ethmoidal labyrinth area was exposed to EHF-radiation during 30 minutes. One phase consisted of 10-15 sessions performed daily. The full treatment course included 4 phases: 

(1) immediately after the surgery treatment;
(2) 1 month past the 1st phase;
(3) 3 months after the 2nd phase;
(4) 6 months after the 3rd phase.

Tolerance to EHF-therapy was good. Relapse and metastases rates reduced independently of position and depth of the invasion area. Observations during 5 years had revealed local and remote signs of tumor generalization in 41.1 % only (while in the control group it was 71.5 %) [N.Deviatkov, 1989; R.Kabisov, 1992; S.Pletnev, 1991].

4.2. Treatment of the Ear, Nose and Throat cancer.
The treatment method described above was used after the surgery.
In the group receiving EHF-therapy the number of suppurative inflammation cases reduced more than twice while the number of patients whose wounds were healed by the first intention increased.
Remote results have shown that relapses (from 29,1 % to 12,0 %) and metastases (from 43,7 to 22,0 %) were reduced more than twice [R.Kabisov, 1992].

4.3. Treatment of the Large Bowel cancer.
EHF-therapy improved immediate and remote results of surgery treatment of the large bowel cancer [R.Kabisov, 1992]:

 

Surgery
and EHF-therapy

Surgery
without EHF-therapy

Healing the wounds by the first intention:

77,7 %

30,4 %

Healing the wounds by the second intention

22,3 %

69,6 %

Relapses:

10,0 %

23,3 %

Metastases:

23,3 %

50,0 %


4.4. Treatment of the Breast cancer.
Patients in the IIb and IIIb stages of diseases undergoing chemical therapy were treated. The course of EHF-therapy consisted of 14-15 sessions performed daily:
(1) 3 sessions prior to chemical therapy;
(2) during treatment and
(3) 3 sessions after chemical therapy.

Treatment results were as following: in combination with EHF, the chemotherapy (without hemo-stimulators) could be done completely without toxic side effects in 95.1 % of patients, as compared to 79.2 % in the control group.

Hemo-protective effect of EHF-therapy realized in that the number of monocytes and lymphocytes in peripheral blood did not reduce. The quantity of leukocytes was less than 3000 only in 4.5 % of cases (in control group - 18 %), and less than 3500-3000 in 13,6 % cases (in control group - 32 %). 

Pyrogenal test, which determined the leukocyte reserve of the marrow revealed post-surgical leukocytosis in 39 % of patients who received EHF-therapy (in the control group it was 20 % only).

There were no reliable data on suppression of the marrow.

As a result of treatment the hemogenic stability and good tolerance to chemo-therapy was revealed, both on account of the reserve blood discharge from debot and due to reduced suppression of marrow by anti-tumor medicines and its active blood generation [S.Pletnev et al., 1985, 1987, 1991]. 

The analogous results were obtained in the other investigations during EHF- stimulation of leukopoiesis while patients were performed chemo-therapy because of the breast cancer [V.Ivakin et al., 1997].

In the same work they demonstrated a possibility to treat different accompanied diseases of cancer patients, including common cold, influenza, adhesive arachnoiditis, high blood pressure, chronic bronchitis, chronic gastritis, peptic ulcer, etc. [V.Ivakin et al., 1997]. 

4.5. Treatment of the Uterus Body cancer (the 2nd stage).
The combined treatment included surgery, EHF-exposure of sternum area during the period of 3 to 8 days after surgery, and 4-5 weeks course of the radiotherapy started on the 15th -16th day after the surgery.

Those patients who received EHF-therapy had immunity protective and immunity modulating effects with preservation of Т- helpers sub-population both after surgery and ray therapy [S.Geshelin et al., 1991; V.Zaporozhan et al., 1991, 1992].

4.6. Treatment of the pulmonary and gastric cancer.
Patients who were operated because of the pulmonary and gastric cancer, were performed 30 minutes EHF-exposure to 4 acupoints. Treatment started on the next day after surgery and included 3-5 sessions. They applied multichannel generator of MM EMR “Luch-EHF” (7,1 mm).

Among patients who received EHF-therapy the number of such post-surgery complications as pneumonia and insolvency of anastamosis was decreased considerably. Basic homeostasis parameters (humoral and cells components of immune system, blood mediators and enzymes) were restored twice as faster as in the control group. A quick improvement of the “functional energetic condition of the body” according to the skin electrical resistance measuring performed by diagnostic apparatus “ROFUS-24K” was observed [N.Lian et al., 1995].

4.7. Treatment of the lymphoma and solid tumors.  
Patients suffering from lymphoma and solid tumors had received radio- or combined therapy. To stimulate hemopoiesis generator of MM EMR “Jav-I” (5,6 and 7,1 mm) was used. 7-10 minutes of EHF-exposure was carried out to both on the sternum and occiput zones or 30 minutes EHF-exposure was performed to the sternum area. Additionally to treat the complications of radio- or combined treatment the local application of MM EMR had been used too. The course of EHF-therapy consisted of 5-15 sessions.

After EHF-therapy the 60 % of patients noticed improvement of their condition. The objective changing the parameters of the peripheral blood was already obtained after 6-8 procedures. Local application of EHF-therapy resulted in releasing or disappearance of edema and pain till the 6-10 sessions. Besides, a quick epitelization of the damaged regions was achieved [L.Korytova et al., 1995].

Thus, the major positive effects of EHF-therapy in combined treatment of malignant neoplasm were as follows:
1) reduction of post-surgical complications;
2) less expressed side effects of chemo-therapy and ray treatment;
3) hemo-protective and immunity-modulating effects;
4) reduced number of relapses and metastases.


5. Indications for EHF-therapy in Oncology

1) Preparation to radical treatment: treatment of accompanying diseases and syndromes, prevention of the toxic effects of radio- and chemo-therapy and increasing tolerance to the radical treatment;

2) Treatment of the complication appeared after radical treatment: (surgery treatment, chemo- and radio-therapy): leukopenia, hypoplastic condition of marrow, toxic side effects of radio- and chemo-therapy, post-surgery suppurative inflammation, etc.;

3) Combination with other synergetic methods of treatment applied in oncology: laser-therapy, narcotic, analgesic or psychotropic remedies, etc.;

4) Treatment of the paraneoplastic syndrome;

5) Palliative EHF-therapy of incurable patients: narco-trancvilazation, analgetic and anti-inflammatory effects, etc;

6) Prevention of tumor process development after combined treatment: metastases, relapses and dissemination.

No direct contra-indications of MM EMR in oncology were known so far.

Thus, almost any oncological patient may be applied EHF-therapy according to indications given above [R.Kabisov et al., 1991; R.Kabisov, 1992; S.Pletnev et al., 1991, 1992; S.Sit'ko et al., 1991].


References:
A.Arinushkina et al., 1997,
E.Binyashevskii et al., 1992,
N.Deviatkov et al., 1987,
N.Deviatkov, 1989,
N.Deviatkov et al., 1991,
N.Deviatkov et al., 1997,
А.Dolgushina, 1997,
I.Fasahkov, 1985,
S.Geshelin et al., 1991,
B.Grubnik et al., 1997,
V.Ivakin et al., 1997],
R.Kabisov, 1991,
R.Kabisov, 1992,
L.Kamalian et al., 1989,
L.Korytova et al., 1995,
N.Lian et al., 1995,
S.Michaelson, 1963,
L.Mkrtchian et al., 1989,
L.Mkrtchian et al., 1991,
D.Myasoedov et al., 1989,
S.Pletnev et al., 1985,
S.Pletnev et al., 1987,
S.Pletnev, 1991,
S.Pletnev et al., 1991,
S.Pletnev et al., 1992,
S.Pletnev, 1995,
S.Pletnev et al., 1995,
A.Presman, 1968,
L.Sevastjanova et al., 1966,
L.Sevastjanova, 1979,
L.Sevastjanova et al., 1985,
S.Sit'ko et al., 1991,
S.Sit'ko et al., 1993,
I.Soloviev et al., 1992,
M.Teppone, 1991,
V.Zaporozhan et al., 1991,
V.Zaporozhan et al., 1992,
V.Zaporozhan et al., 1993,
V.Zaporozhan et al., 1995,
V.Zaporozhan et al., 1997,
E.Zubenkova, 1991
.

[Home] [Articles] [Catalogue]